Dr. Arun on Ongoing Research in Triple-Negative Breast Cancer

Banu Arun, MD
Published: Monday, Jul 23, 2018



Banu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research in triple-negative breast cancer (TNBC).

TNBC is a very heterogeneous disease. The disease can be broken down into multiple subtypes and can most likely be targeted with multiple agents that target different pathways, says Arun. Physicians are pretty confident that a single agent will not be enough to treat the disease, unless they can identify a very specific pathway that is involved in the proliferation of that subtype.

Physicians have yet to reach that conclusion, says Arun, and as there are no existing biomarkers of response, research continues to investigate different therapeutic agents. Physicians are now starting to explore targeted therapies with immunotherapy and immunomodulation as well as targeting the PI3K/mTOR/AKT pathway. There are some antibody-drug conjugates under development as well.

Another approach is to target the androgen receptor in TNBC, though none of these approaches are standard of care, notes Arun.
SELECTED
LANGUAGE


Banu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research in triple-negative breast cancer (TNBC).

TNBC is a very heterogeneous disease. The disease can be broken down into multiple subtypes and can most likely be targeted with multiple agents that target different pathways, says Arun. Physicians are pretty confident that a single agent will not be enough to treat the disease, unless they can identify a very specific pathway that is involved in the proliferation of that subtype.

Physicians have yet to reach that conclusion, says Arun, and as there are no existing biomarkers of response, research continues to investigate different therapeutic agents. Physicians are now starting to explore targeted therapies with immunotherapy and immunomodulation as well as targeting the PI3K/mTOR/AKT pathway. There are some antibody-drug conjugates under development as well.

Another approach is to target the androgen receptor in TNBC, though none of these approaches are standard of care, notes Arun.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x